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Results of the "Amniostat-FLM" assay, a rapid semiquantitative test for phosphatidylglycerol, were compared with determinations of the lecithin/sphingomyelin (US) ratio, with phosphatidylglycerol measured by two-dimensional thin-layer chromatography, and with results of the "shake test" for 94 specimens of amniotic fluid. Correlation between results with the Amniostat and the other tests was excellent. All four tests are very accurate when predicting lung maturity. The predictive value of a negative test, i.e., that hyaline membrane disease would not occur, was between 92 and 100%. However, the accuracy of predicted lung immaturity is poor. For all four tests, predictions of lung immaturity were incorrect in more than 50% of the cases. Of the 49 infants born within 72 h of testing, none developed hyaline membrane disease when phosphatidylglycerol was detectable by either method or when the shake test indicated fetal lung maturity, but three infants with US ratio >2/1 did develop the disease. The Amniostat provides a rapid screening method for detecting phosphatidylglycerol in amniotic fluid, which could well replace the thin-layer chromatographic method for measuring phosphatidylglycerol in the panel of diagnostic tests for fetal lung maturity.
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Since 1971, when Gluck et al.
(1) used thin-layer chromatography (TLC) to measure lecithin and sphingomyelin in amniotic fluid, this method has been the standard for assessing fetal lung maturity (2), an L/S ratio of 2/1 or greater generally indicating lung maturity. However, about 3% of all infants whose test results suggest lung maturity develop HMD (3). These are usually infants of diabetic or Rh-negative mothers. Moreover, some infants do not develop HMD even though born soon after a test has indicated lung immaturity; i.e., the proportion of false-positive results is substantial (4) .
In addition, technical problems associated with the L/S ratio make interpretation of results difficult, i.e., if the amnioticfluid is contaminated with blood or mecomum, has not been kept cold, or has been centrifuged under improper conditions (5). Because the TLC method requires about 2 h of technologist time and 3 h to provide a result, its use in many laboratories is restricted to regular weekday working hours.
In an attempt to increase the predictive value of these tests with amniotic fluid, the quantities of other phospholipids such as phosphatidylethanolamine, phosphatidylinositol, and phosphatidylglycerol (PG) were used to define a "lung profile" (3, 6). However, this further complicated the evaluation when it became obvious that various components of the lung profile could mature at different rates, producing confusion about which of these best reflected lung maturity (5) .
Other methods proposed for determining fetal lung maturity are based on physical attributes of the amniotic fluid such as its microviscosity or surface tension-e.g., the "shake test" (7) , which evaluates the fluid's surface tension in terms of the stability of a ring of bubbles.
PG, which appears in amniotic fluid near the end of gestation, has been suggested as a more specific indicator of lung maturity than the uS ratio (8). Because it is not found in the blood, this phospholipid can serve as an indicator of lung maturity even in blood-contaminated amniotic fluid (9) .
Although it provides useful clinical data, the panel of tests
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Reason for study 7, 1984 used in our laboratory for the evaluation of fetal status (measurement of the L' ratio by one-dimensional TLC, measurement of PG by two-dimensional TLC, and the shake test) is labor intensive and thus expensive. We therefore evaluated a kit that is promoted as a quick and accurate assay that can provide reliable information on a 24 h basis: the "Amniostat-FLM" (Hana Biologics, Berkeley, CA), a semiquantitative immunological test for PG in amniotic fluid. The results of our study, conducted to determine whether we could replace part of our test panel with the Amniostat, are reported here.
Materials and Methods

Samples
The study populationcomprised 88 patients undergoing transabdominal amniocentesis for evaluation of fetal maturity at Grace Hospital between April and December 1983. The estimated gestational age at the time of study ranged from 28 to 41 weeks.
We studied 94 samples of amniotic fluid. In most of the cases the purpose of the amniocentesis was to estimate fetal lung maturity in patients where intervention with the pregnancy was being considered. A few studies involved measurement of optical absorbance of amniotic fluid to evaluate rhesus isoimmunization near 30 weeks of gestation. Table 1 summarizes the clinical data for all specimens studied.
In 12 specimens seen to be contaminated with blood or meconium we evaluated only PG. In 14 cases there was insufficient specimen to perform a shake test. In three cases, the PG-TLC was uninterpretable for technical reasons. Thus, in all there were 75 uncontaminated specimens on which the full panel of tests was performed.
Samples of amniotic fluid were obtained while collection was monitored with ultrasound; these were promptly placed on ice and transported directly to the laboratory. A 3-mL aliquot was set aside for the shake test; the rest was centrifuged at 1000 x g for 5 mm in a refrigerated centrifuge. All samples were analyzed without delay.
Procedures
Wedetermined thei.isratio by one-dimensional TLC and densitometry after precipitation of the sample with cold acetone. We used silica gel F-254 TLC plates (Brinkmann Instruments, Toronto, Ontario, Canada) with chloroform! methanollammomum hydroxide (130/50/8 by vol) as devel- Table 1 . Clinical Data for All Cases (n = 94) Time to delivery, h oping solvent. Results were classified as "immature," "transitional," or "mature," respectively, for us ratios of 1/1, 1.5/1, or 2/1 or greater.
We measured PG by two-dimensional TLC, using a silica gel plate containing dilute (5/95 by vol) NH4OH (Supelco Inc., Bellafonte, PA),eluting with chloroform/methanol/acetic acid/water (65/25/4/4) for the first dimension and with chloroform!methanol/ammonium (65/25/5) for the second dimension. Results were classified as "absent," "trace," or "obviously present."
Results for the shake test (7), which was done on the 80 samples for which fluid was available, were classified as "immature"
(unstable ring of bubbles at the air-liquid interface), "transitional" (stable, complete ring in first tube only), or "mature" (stable, complete ring of bubbles in two or more tubes).
The Amniostat-FLM test was performed in accordance with the manufacturer's instructions except that we centrifuged the fluid for 5 mm at 1000 x g rather than 500 x g.
We elected to process the fluid this way to speed sample handling and to maintain uniformity among the tests being evaluated, because the other tests required centrifugation at 1000 x g. Aware that centrifuge speed may significantly affect evaluation of amniotic fluid parameters (10), we compared the Amniostat results for 12 amniotic fluid specimens by centrifuging (for 5 mm) one aliquot at 500 x g and a second at 1000 x g. There were no discordant results; the same five samples were positive and the same seven negative at each g-force.
Supplied Because both the L' ratio and the results of the shake test are altered by contamination, we used only the twodimensional TLC and the Amniostat test for fluid that appeared to be contaminated by blood or meconium.
When present, a history of maternal disease such as >72 diabetes or rhesus isoimmunization was noted for the corresponding sample. Neonatal outcome was determined by the neonatologist, using accepted clinical and radiological criteria for the diagnosis of HMD (11).
Statistics
The laboratory and clinical data were evaluated by use of statistical programs (12). A p-value <0.05 was considered significant.
A test result was considered to be positive when it predicted that the lung status was immature or transitional. A negative test result predicted that the lungs were mature and that respiratory distress syndrome would not occur. sis. The clinical characteristics of their babies, eight of whom had HMD, are summarized in Table 2 . Three babies were classified as having Grade 2 HMI) and five as Grade 1. None required long-term intensive care. In three of these cases, while all other tests predicted immaturity, the US ratio was 2/1 ("mature" by our standard criteria). Two were infants of diabetic mothers, one of an Rh-negative mother. Six infants had transient mild respiratory distress or "wet lung syndrome," and were briefly treated with environmental oxygen. This condition is considered to be distinct from respiratory distress syndrome due to HMD, and is not related to maturity of the pulmonary surfactant system (13). Table 3 we compare PG by Amniostat and by TLC, together with the correlations of the other amniotic fluid parameters. All tests correlate well.
Results
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The predictive value of each amniotic fluid parameter in terms of actual fetal outcome is shown in Table 4 . In no test did the predictive value of a positive test exceed 50%.
In 10 of the 11 cases in which the fluid could not be used for US ratio or shake test because of blood or meconium contamination, the result for PG by TLC and Amniostat was the same. In the other case, PG was present on TLC but absent on Amniostat, and the 35-week old infant delivered within 24 h did not develop HMD. One of the other 10 infants was also delivered within 24 h. PG was not detectable by either method but the infant, a severely compromised infant of an Rh-negative mother who received several HMD exchange transfusions, did not develop HMD.
(n 8)
For nine (10%) cases the PG and Amniostat results were clearly discordant. In six of these PG was present by TLC, 2526 but absent by Amniostat, while in the other three the 444 reverse was true. In four of the nine casesin which the baby was born within 48 h there was no HMD. In one of the four cases PG was present on Amniostat but absent on TLC, and in three PG was present on TLC but not on Amniostat. These numbers are insufficient to determine the clinical significance of the difference, particularly with the high 3 incidence of false positives for both tests.
In four cases, the PG-TLC was uninterpretable for techni- 
Discussion
The correlation among the four tests is good (Table 3) , with concordant classification of samples as mature or immature in most cases. However, when an US ratio of 2/1 is used as the cutoff value for maturity, approximately a quarter of the "mature" samples would have been classed as immature had any of the other three tests been performed alone. When PG, as measured by either method, is compared with results by the shake test, almost half of"mature" samples by the shake test would be classed as immature by PG. This highlights the importance of providing a panel of tests to interpret in relation to the clinical situation.
When clinical outcome is compared with results of laboratory tests (Table 4) , it is apparent that sensitivity is excellent, but specificity less so, for all four tests.
All four tests share the problems of poor predictive value when a positive test result is obtained, as has been previously reported (2, 3, 14) . The most nearly accurate predictor of HMD is a positive US test when a ratio of 2/1 or greater is considered mature. However, in this case the predictive value of a negative test drops to 92%, as compared with 100% for each of the other tests. This could result in HMD in a baby with a "mature" test result, as is known to occur in the infant of a diabetic or an Rh-negative mother. The predictive value of a positive test for the other three tests ranged from 33% to 44%. This could potentially prompt the undue prolongation of a hazardous pregnancy or unnecessary use of therapy with steroids.
A mature or negative result for PG by either method or by shake test in this series accurately indicated that the infant would not develop HMD.
The correlation between the Aniniostat and the TLC method for PG is good. In 10% of the cases the results differed, but in view of the high incidence of false positives for both tests and the few cases followed by birth within 72 h, it is not always obvious which is correct. The Amniostat has the major advantage of being faster than the TLC method. The slide test takes about 30 mm to process and can clearly be offered on an emergency basis. The Amniostat requires about 1 mL of fluid; 6 mL is needed for the TLC method.
The manufacturer of the Amniostat recommends centrifugation at 500 x g because their original development work was carried out at 500 x g. We preferred to centrifugethe entire amniotic fluid specimen at the speed used in our TLC methods (1000 x g). This facilitates the use of the test in a routine laboratory such as ours that offers a panel of lung maturity tests. Preliminary evaluation comparisons with 12 specimens showed that this did not affect the performance of the test. The manufacturer confirmed that use of 1000 x g for only 5 nun would be unlikely to increase the precipitation of PG enough to affect test results.
A laboratory that is planning to use this kit must have the necessary equipment, e.g., a refrigerated centrifuge and accurate micropipettes, and be aware that potential technical problems such as dirty slides, incorrect sample dilutions, or mixing problems can affect interpretation. Experience in reading the slides is needed to produce consistently reproducible results. Awareness of the high incidence of falsepositive predictions is also important. Should the Amniostat result indicate that PG is definitely present, it is highly likely that HMD will not occur. However, if no PG is detected by Amniostat, there is only a 40% chance that HMD will occur. This test therefore provides a useful screen, but should only be offered by a laboratory that is capable of backing up the Amniostat test with a determination of the 115 ratio.
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